Valeant Pharmaceuticals International’s new CEO, Joseph Papa, addressed investors directly for the first time Monday morning since he took over earlier this month.
Speaking at the UBS Global Healthcare Conference in New York, he declined to update Valeant’s 2016 sales and earnings guidance, issued in March. But he did tell the gathered crowd that his philosophy on guidance is to “under-promise and over-deliver.”
Given Valeant’s recent turmoil, that sounds wise. But his philosophy might come as a surprise to shareholders at Perrigo, where Mr. Papa served as chief executive for over a decade before leaving for Valeant.
After all, Perrigo had to sharply cut full-year guidance in April. Additionally, on the first quarter earnings call earlier this month, new Perrigo CEO John Hendrickson said “our recent track record of performance against our own expectations is unacceptable.”
The change to Mr. Papa’s philosophy must have been a recent one.
By Charley Grant
Source: Wall Street Journal
After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.
SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.
After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.
